

# Author Index Volume 56 (2017)

The issue number is given in front of the pagination

- Aarsland, D., see Bergland, A.K. (2) 575–584
- Aarsland, D., see Chong, J.R. (1) 157–166
- Abrescia, P., see Benussi, L. (2) 825–833
- Adolfsson, O., see Theunis, C. (2) 585–599
- Agüera-Ortíz, L., see Ismail, Z. (3) 929–938
- Agyemang, C., I.E. van de Vorst, H.L. Koek, M.I.  
Bots, A. Seixas, M. Norredam, U. Ikram, K.  
Stronks and I. Vaartjes, Ethnic Variations  
in Prognosis of Patients with Dementia: A  
Prospective Nationwide Registry Linkage  
Study in The Netherlands (1) 205–213
- Ahmed, M.E., see Lu, Y. (4) 1469–1484
- Ahonen, R., see Koponen, M. (1) 107–118
- Aisen, P.S., see Sokolow, S. (1) 229–237
- Aizenstein, O., see Molad, J. (4) 1293–1299
- Akatsu, H., see Sabbagh, M.N. (2) 441–446
- Akazawa, K., see Kuriyama, N. (4) 1253–1262
- Akiba, C., see Jurjević, I. (1) 317–325
- Alcolea, D., see Tell-Martí, G. (3) 1065–1074
- Alegret, M., see Boada, M. (1) 129–143
- Allen, M., see N'Songo, A. (4) 1215–1222
- Almkvist, O., see Li, X. (1) 327–334
- Alperin, N., see Loewenstein, D.A. (3) 1119–1126
- Ambrosi, A., see Ferrari, L. (3) 1101–1107
- Amen, D.G., B. Darmal, C.A. Raji, W. Bao, L.  
Jorandby, S. Meysami and C.S. Raghavendra,  
Discriminative Properties of Hippocampal  
Hypoperfusion in Marijuana Users Compared  
to Healthy Controls: Implications for Marijuana  
Administration in Alzheimer's Dementia (1)  
261–273
- Amenta, F., see Carotenuto, A. (2) 805–815
- Amin, N.D., see Shukla, V. (1) 335–349
- An, H., see Kim, Y.J. (3) 1007–1014
- Anand, K., see Sabbagh, M.N. (2) 441–446
- Anaya, F., see Boada, M. (1) 129–143
- Angus, J.A., see Betrie, A.H. (2) 849–860
- Anstey, K.J., K. Ashby-Mitchell and R. Peters,  
Updating the Evidence on the Association  
between Serum Cholesterol and Risk of Late-  
Life Dementia: Review and Meta-Analysis (1)  
215–228
- Antonell, A., see Tell-Martí, G. (3) 1065–1074
- Apostolova, I., C. Lange, A. Roberts, H.J. Igel, A.  
Mäurer, S. Liese, M. Estrella, V. Prasad, E.  
Stechl, G. Lämmler, E. Steinhagen-Thiessen  
and R. Buchert, Challenges in Screening and  
Recruitment for a Neuroimaging Study in  
Cognitively Impaired Geriatric Inpatients (1)  
197–204
- Apostolova, L.G., see Sokolow, S. (1) 229–237
- Arai, H., see Jurjević, I. (1) 317–325
- Araujo, J.A., see Borghys, H. (2) 763–774
- Archetti, S., see Ferrari, R. (4) 1271–1278
- Arighi, A., see van Waalwijk van Doorn, L.J.C. (2)  
543–555
- Arnold, S.E., see Yarchoan, M. (2) 699–706
- Artyuhov, A.S., see Dashinimaev, E.B. (2) 835–847
- Arvanitakis, Z., see Yarchoan, M. (2) 699–706
- Ashby-Mitchell, K., see Anstey, K.J. (1) 215–228
- Ashe, K.H., see Liu, P. (2) 743–761
- Asmann, Y., see N'Songo, A. (4) 1215–1222
- Asthana, S., see Law, L.L. (1) 351–359
- Attems, J., see Chong, J.R. (1) 157–166
- Audoin, B., see Sellal, F. (1) 37–46
- Auger, L.E., see Last, N. (1) 275–286
- Auriel, E., see Molad, J. (4) 1293–1299
- Avila, J., see Gomez-Ramos, A. (3) 977–990
- Axmacher, N., see Kunz, L. (3) 1135–1144
- Ayres, A., see Valenti, R. (4) 1223–1227
- Ayton, S., see Betrie, A.H. (2) 849–860
- Baazaoui, N., M. Flory and K. Iqbal, Synaptic  
Compensation as a Probable Cause of Prolonged  
Mild Cognitive Impairment in Alzheimer's  
Disease: Implications from a Transgenic Mouse  
Model of the Disease (4) 1385–1401
- Bäckman, L., see Khan, W. (3) 1159–1174
- Badenas, C., see Tell-Martí, G. (3) 1065–1074
- Bagnoli, S., see Ferrari, R. (4) 1271–1278
- Bai, F., see Su, F. (2) 491–507
- Baldeiras, I., see van Waalwijk van Doorn, L.J.C. (2)  
543–555
- Ballard, C.G., see Chong, J.R. (1) 157–166

- Banaschewski, T., see Khan, W. (3) 1159–1174
- Bao, W., see Amen, D.G. (1) 261–273
- Barão, S., see Timmers, M. (4) 1437–1449
- Barcs, G., see Horváth, A. (3) 1175–1183
- Barker, G.J., see Khan, W. (3) 1159–1174
- Barkhof, F., see Louwersheimer, E. (1) 63–74
- Baroni, M., see Boccardi, V. (1) 239–248
- Barrett, M.S., see Siegel, A.M.
- Barrio, J.R., see Doran, E. (2) 459–470
- Barthel, H., see Sabbagh, M.N. (2) 441–446
- Bastian, F.O., Combined Creutzfeldt-Jakob/Alzheimer's Disease Cases are Important in Search for Microbes in Alzheimer's Disease (3) 867–876
- Batchelor, J., see McKinnon, A.C. (4) 1373–1384
- Bautz, A., see Thygesen, L.C. (4) 1429–1435
- Behrens, T.W., see Haddick, P.C.G. (3) 1037–1054
- Belliard, S., see Gaubert, M. (2) 717–731
- Ben Assayag, E., see Molad, J. (4) 1293–1299
- Ben Bashat, D., see Molad, J. (4) 1293–1299
- Bendlin, B.B., see Law, L.L. (1) 351–359
- Benedí, J., see González-Muñoz, M.J. (3) 917–927
- Bennett, D.A., see Yarchoan, M. (2) 699–706
- Bennett, D.A., see Yu, L. (4) 1485–1493
- Benussi, L., R. Ghidoni, F.D. Piaz, G. Binetti, G. Di Iorio and P. Abrescia, The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimer's Disease (2) 825–833
- Benussi, L., see Ferrari, R. (4) 1271–1278
- Bergland, A.K., I. Dalen, A.I. Larsen, D. Aarsland and H. Soennesyn, Effect of Vascular Risk Factors on the Progression of Mild Alzheimer's Disease and Lewy Body Dementia (2) 575–584
- Bernardi, L., see Ferrari, R. (4) 1271–1278
- Betrie, A.H., S. Ayton, A.I. Bush, J.A. Angus, P. Lei, C.E. Wright, Evidence of a Cardiovascular Function for Microtubule-Associated Protein Tau (2) 849–860
- Bhangale, T.R., see Haddick, P.C.G. (3) 1037–1054
- Bhati, M.T., see Siegel, A.M.
- Biegon, A., see Sundermann, E.E. (3) 947–957
- Bielarczyk, H., see Zyś, M. (3) 1145–1158
- Binetti, G., see Benussi, L. (2) 825–833
- Binetti, G., see Ferrari, R. (4) 1271–1278
- Binukumar, B.K., see Shukla, V. (1) 335–349
- Blennow, K., see Li, X. (1) 327–334
- Blennow, K., see Toombs, J. (3) 885–891
- Blennow, K., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Blusztajn, J.K., see Wang, E. (1) 47–61
- Boada, M., F. Anaya, P. Ortiz, J. Olazarán, J.R. Shua-Haim, T.O. Obisesan, I. Hernández, J. Muñoz, M. Buendia, M. Alegret, A. Lafuente, L. Tárraga, L. Núñez, M. Torres, J.R. Grifols, I. Ferrer, O.L. Lopez and A. Páez, Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial (1) 129–143
- Boccardi, V., M. Baroni, N. Smirne, A. Clodomiro, S. Ercolani, A. Longo, C. Ruggiero, A.C. Bruni and P. Mecocci, Short-Term Response is not Predictive of Long-Term Response to Acetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer's Disease: A "Real World" Study (1) 239–248
- Bocti, C., see Castellano, C.-A. (4) 1459–1468
- Boddaert, J., see Zerah, L. (1) 145–156
- Bogert, J., see Timmers, M. (4) 1437–1449
- Bohlken, J., see Jacob, L. (1) 379–384
- Bohlken, J., see Jacob, L. (4) 1519–1524
- Bokde, A.L.W., see Khan, W. (3) 1159–1174
- Bolshakov, A.P., see Dashinimaev, E.B. (2) 835–847
- Bondi, M.W., see Granholm, E.L. (4) 1419–1428
- Bonomi, E., see Ferrari, R. (4) 1271–1278
- Boots, E.A., see Law, L.L. (1) 351–359
- Borchelt, D.R., see Liu, P. (2) 743–761
- Borghgraef, P., see Theunis, C. (2) 585–599
- Borghys, H., B. Van Broeck, D. Dhuyvetter, T. Jacobs, K. de Waepenaert, T. Erkens, M. Brooks, S. Thevarkunnel and J.A. Araujo, Young to Middle-Aged Dogs with High Amyloid-β Levels in Cerebrospinal Fluid are Impaired on Learning in Standard Cognition tests (2) 763–774
- Bornstein, N.M., see Molad, J. (4) 1293–1299
- Borroni, B., see Ferrari, R. (4) 1271–1278
- Borsello, T., see Buccarello, L. (4) 1279–1292
- Bots, M.L., see Agyemang, C. (1) 205–213
- Boulouis, G., see Valenti, R. (4) 1223–1227
- Bouwman, F.H., see Slot, R.E.R. (2) 687–697
- Boyle, P.A., see Yu, L. (4) 1485–1493
- Bozzali, M., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Brandscheid, C., F. Schuck, S. Reinhardt, K.-H. Schäfer, C.U. Pietrzik, M. Grimm, T. Hartmann, A. Schwierz and K. Endres, Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimer's Mouse Model (2) 775–788
- Brann, D., see Lu, Y. (4) 1469–1484

- Bremer, J.A.E., see Van Mierlo, L.D. (1) 249–259
- Brodaty, H., see Ismail, Z. (3) 929–938
- Brooks, M., see Borghys, H. (2) 763–774
- Brooks, S.W., A.C. Dykes and B.G. Schreurs, A High-Cholesterol Diet Increases 27-Hydroxycholesterol and Modifies Estrogen Receptor Expression and Neurodegeneration in Rabbit Hippocampus (1) 185–196
- Bruce, D.G., see Peters, K.E. (3) 1127–1133
- Bruni, A.C., see Boccardi, V. (1) 239–248
- Bruni, A.C., see Ferrari, R. (4) 1271–1278
- Buccarello, L., G. Grignaschi, A.M. Castaldo, A. Di Giancamillo, C. Domenehini, R.C. Melcangi and T. Borsello, Sex Impact on Tau-Aggregation and Postsynaptic Protein Levels in the P301L Mouse Model of Tauopathy (4) 1279–1292
- Büchel, C., see Khan, W. (3) 1159–1174
- Buchert, R., see Apostolova, I. (1) 197–204
- Buendia, M., see Boada, M. (1) 129–143
- Bush, A.I., see Betrie, A.H. (2) 849–860
- Caga, J., see Kaizik, C. (3) 1109–1117
- Cai, J., see Li, L. (4) 1403–1417
- Caltagirone, C., see Gelfo, F. (4) 1505–1518
- Calvo-Garrido, J., see Persson, T. (2) 601–617
- Camino, J., see Kaizik, C. (3) 1109–1117
- Campion, D., see Sellal, F. (1) 37–46
- Caon, M., see Ienca, M. (4) 1301–1340
- Capp, K., see Loewenstein, D.A. (3) 1119–1126
- Carlsson, C.M., see Law, L.L. (1) 351–359
- Carotenuto, A., R. Rea, E. Traini, A.M. Fasanaro, G. Ricci, V. Manzo and F. Amenta, The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial (2) 805–815
- Carrasquillo, M.M., see N'Songo, A. (4) 1215–1222
- Carter, A.Y., see Fitz, N.F. (3) 1075–1085
- Casson, R.J., see Chidlow, G. (2) 655–675
- Castagna, A., see Gareri, P. (2) 557–565
- Castaldo, A.M., see Buccarello, L. (4) 1279–1292
- Castellano, C.-A., N. Paquet, I.J. Dionne, H. Imbeault, F. Langlois, E. Croteau, S. Tremblay, M. Fortier, J.J. Matte, G. Lacombe, T. Fülöp, C. Bocti and S.C. Cunnane, A 3-Month Aerobic Training Program Improves Brain Energy Metabolism in Mild Alzheimer's Disease: Preliminary Results from a Neuroimaging Study (4) 1459–1468
- Castelo-Branco, M., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Castronio, E.L., see Fitz, N.F. (3) 1075–1085
- Cavedo, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Cedazo-Mínguez, Á., see Persson, T. (2) 601–617
- Chai, Y.L., see Chong, J.R. (1) 157–166
- Chang, K.J., C.H. Hong, K.S. Lee, D.R. Kang, J.D. Lee, S.H. Choi, S.Y. Kim, D.L. Na, S.W. Seo, D.-K. Kim, Y. Lee, Y.K. Chung, K.Y. Lim, J.S. Noh, J. Park and S.J. Son, Mortality Risk after Diagnosis of Early-Onset Alzheimer's Disease versus Late-Onset Alzheimer's Disease: A Propensity Score Matching Analysis (4) 1341–1348
- Charidimou, A., see Valenti, R. (4) 1223–1227
- Chen, C., see Shen, L. (1) 361–378
- Chen, C.P., see Chong, J.R. (1) 157–166
- Chen, J., L. Zhan, X. Lu, C. Xiao and N. Sun, The Alteration of ZiBuPiYin Recipe on Proteomic Profiling of Forebrain Postsynaptic Density of db/db Mice with Diabetes-Associated Cognitive Decline (2) 471–489
- Chen, L., see Sokolow, S. (1) 229–237
- Chen, Y., see Shen, L. (1) 361–378
- Chételat, G., see Gaubert, M. (2) 717–731
- Chidlow, G., J.P.M. Wood, J. Manavis, J. Finnie and R.J. Casson, Investigations into Retinal Pathology in the Early Stages of a Mouse Model of Alzheimer's Disease (2) 655–675
- Choi, S.H., see Chang, K.J. (4) 1341–1348
- Chong, J.R., Y.L. Chai, J.H. Lee, D. Howlett, J. Attems, C.G. Ballard, D. Aarsland, P.T. Francis, C.P. Chen and M.K.P. Lai, Increased Transforming Growth Factor  $\beta$ 2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble  $A\beta_{42}$  Load (1) 157–166
- Chung, Y.K., see Chang, K.J. (4) 1341–1348
- Cieslak, A., see Ismail, Z. (3) 929–938
- Claassen, J.A.H.R., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Clarimón, J., see Tell-Martí, G. (3) 1065–1074
- Clodomiro, A., see Boccardi, V. (1) 239–248
- Cohen-Bittan, J., see Zerah, L. (1) 145–156
- Cohn-Hokke, P.E., see Louwersheimer, E. (1) 63–74
- Colao, R., see Ferrari, R. (4) 1271–1278
- Comi, G., see Ferrari, L. (3) 1101–1107
- Conforti, R., see Gareri, P. (2) 557–565
- Conrod, P., see Khan, W. (3) 1159–1174
- Cook, D.B., see Law, L.L. (1) 351–359
- Coppèdè, F., see Stoccero, A. (4) 1451–1457
- Cotroneo, A.M., see Gareri, P. (2) 557–565
- Crespo-Biel, N., see Theunis, C. (2) 585–599

- Crocco, E., see Loewenstein, D.A. (3) 1119–1126
- Cross, N.E., see McKinnon, A.C. (4) 1373–1384
- Croteau, E., see Castellano, C.-A. (4) 1459–1468
- Cruchaga, C., see Haddick, P.C.G. (3) 1037–1054
- Cui, D., see Xie, B. (1) 391–401
- Cui, M.-Z., see Hu, C. (4) 1263–1269
- Cummings, J., see Ismail, Z. (3) 929–938
- Cunnane, S.C., see Castellano, C.-A. (4) 1459–1468
- Cupidi, C., see Ferrari, R. (4) 1271–1278
- Curiel, R.E., see Loewenstein, D.A. (3) 1119–1126
- Curiel, R.E., see Matías-Guiu, J.A. (2) 733–742
- Cutuli, D., see Gelfo, F. (4) 1505–1518
- Czaja, S.J., see Loewenstein, D.A. (3) 1119–1126
- D'Amelio, M., see Gelfo, F. (4) 1505–1518
- Dai, S.-X., see Wang, Q. (4) 1525–1539
- Dai, Z., see Wang, Z. (1) 415–428
- Dalen, I., see Bergland, A.K. (2) 575–584
- Darmal, B., see Amen, D.G. (1) 261–273
- Dartigues, J.-F., see Pimouquet, C. (2) 509–517
- Dashinimaev, E.B., A.S. Artyuhov, A.P. Bolshakov, E.A. Vorotelyak and A.V. Vasiliev, Neurons Derived from Induced Pluripotent Stem Cells of Patients with Down Syndrome Reproduce Early Stages of Alzheimer's Disease Type Pathology in vitro (2) 835–847
- Davidsdottir, S., see Valenti, R. (4) 1223–1227
- Davis, T.M.E., see Peters, K.E. (3) 1127–1133
- Davis, W.A., see Peters, K.E. (3) 1127–1133
- De Bartolo, P., see Gelfo, F. (4) 1505–1518
- de la Monte, S., see Lee, H.-K. (3) 1015–1036
- de La Sayette, V., see Gaubert, M. (2) 717–731
- de Oliveira, C.R., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- de Strooper, B., see Timmers, M. (4) 1437–1449
- de Waepenaert, K., see Borghys, H. (2) 763–774
- De Waepenaert, K., see Timmers, M. (4) 1437–1449
- Desgranges, B., see Gaubert, M. (2) 717–731
- Devijver, H., see Theunis, C. (2) 585–599
- Dhar, A., see Sellal, F. (1) 37–46
- Dhuyvetter, D., see Borghys, H. (2) 763–774
- Di Giancamillo, A., see Buccarello, L. (4) 1279–1292
- Di Iorio, G., see Benussi, L. (2) 825–833
- Dionne, I.J., see Castellano, C.-A. (4) 1459–1468
- DiPucchio, Z.Y., see Sellal, F. (1) 37–46
- Domeneghini, C., see Buccarello, L. (4) 1279–1292
- Dong, J., see Wu, L. (3) 893–898
- Dong, Y., see Lu, Y. (4) 1469–1484
- Doody, R.S., see Jia, J. (4) 1495–1504
- Doran, E., D. Keator, E. Head, M.J. Phelan, R. Kim, M. Totoiu, J.R. Barrio, G.W. Small, S.G. Potkin and I.T. Lott, Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP (2) 459–470
- Dougherty, R.J., see Law, L.L. (1) 351–359
- Doumpoulakis, S., see Zygouris, S. (2) 619–627
- Dowling, N.M., see Law, L.L. (1) 351–359
- Duara, R., see Loewenstein, D.A. (3) 1119–1126
- Duara, R., see N'Songo, A. (4) 1215–1222
- Duffy, S.L., see McKinnon, A.C. (4) 1373–1384
- Dykes, A.C., see Brooks, S.W. (1) 185–196
- Dyś, A., see Zyśk, M. (3) 1145–1158
- Ebel, D.L., C.G. Torkilsen and T.D. Ostrowski, Blunted Respiratory Responses in the Streptozotocin-Induced Alzheimer's Disease Rat Model (3) 1197–1211
- Edwards, D.F., see Law, L.L. (1) 351–359
- Egret, S., see Gaubert, M. (2) 717–731
- Einerson, J.A., see Law, L.L. (1) 351–359
- Elger, B., see Ienca, M. (4) 1301–1340
- Elman, J.A., see Granholm, E.L. (4) 1419–1428
- Emek-Savaş, D.D., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Emon, M.A.E.K., A.T. Kodamullil, R. Karki, E. Younesi and M. Hofmann-Apitius, Using Drugs as Molecular Probes: A Computational Chemical Biology Approach in Neurodegenerative Diseases (2) 677–686
- Endres, K., see Brandscheid, C. (2) 775–788
- Engelborghs, S., see Timmers, M. (4) 1437–1449
- Ercolani, S., see Boccardi, V. (1) 239–248
- Eren, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Erkens, T., see Borghys, H. (2) 763–774
- Ertekin-Taner, N., see N'Songo, A. (4) 1215–1222
- Escott-Price, V., see Morgan, A.R. (1) 25–36
- Estrella, M., see Apostolova, I. (1) 197–204
- Eusebi, P., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Eustache, F., see Gaubert, M. (2) 717–731
- Fabrice, J., see Ienca, M. (4) 1301–1340
- Fang, H., see Fenesi, B. (1) 297–303
- Farotti, L., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Farrer, L.A., see Haddick, P.C.G. (3) 1037–1054
- Fasanaro, A.M., see Carotenuto, A. (2) 805–815
- Fenesi, B., H. Fang, A. Kovacevic, M. Oremus, P. Raina and J.J. Heisz, Physical Exercise Moderates the Relationship of Apolipoprotein E (APOE) Genotype and Dementia Risk: A Population-Based Study (1) 297–303
- Feng, N., see Li, L. (4) 1403–1417

- Feng, R., see Li, L. (4) 1403–1417
- Fenoglio, C., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Fernández-Castro, A., see Matías-Guiu, J.A. (2) 733–742
- Fernández-Matarrubia, M., see Matías-Guiu, J.A. (2) 733–742
- Fernández-Santiago, R., see Tell-Martí, G. (3) 1065–1074
- Ferrari, L., S.-C. Huang, G. Magnani, A. Ambrosi, G. Comi and L. Leocani, Optical Coherence Tomography Reveals Retinal Neuroaxonal Thinning in Frontotemporal Dementia as in Alzheimer's Disease (3) 1101–1107
- Ferrari, R., M. Grassi, F. Graziano, F. Palluzzi, S. Archetti, E. Bonomi, A.C. Bruni, R.G. Maletta, L. Bernardi, C. Cupidi, R. Colao, I. Rainero, E. Rubino, L. Pinessi, D. Galimberti, E. Scarpini, M. Serpente, B. Nacmias, I. Piaceri, S. Bagnoli, G. Rossi, G. Giaccone, F. Tagliavini, L. Benussi, G. Binetti, R. Ghidoni, A. Singleton, J. Hardy, P. Momeni, A. Padovani and B. Borroni, Effects of Multiple Genetic Loci on Age at Onset in Frontotemporal Dementia (4) 1271–1278
- Ferrer, I., see Boada, M. (1) 129–143
- Ferri, R., see Stoccero, A. (4) 1451–1457
- Finnie, J., see Chidlow, G. (2) 655–675
- Fischer, C.E., see Hird, M.A. (2) 447–452
- Fischer, C.E., see Ismail, Z. (3) 929–938
- Fitz, N.F., A.Y. Carter, V. Tapias, E.L. Castranio, R. Kodali, I. Lefterov and R. Koldamova, ABCA1 Deficiency Affects Basal Cognitive Deficits and Dendritic Density in Mice (3) 1075–1085
- Flor, H., see Khan, W. (3) 1159–1174
- Flory, M., see Baazaoui, N. (4) 1385–1401
- Foiani, M.S., see Toombs, J. (3) 885–891
- Forster, C.L., see Liu, P. (2) 743–761
- Fortea, J., see Tell-Martí, G. (3) 1065–1074
- Fortier, M., see Castellano, C.-A. (4) 1459–1468
- Fotiadis, P., see Valenti, R. (4) 1223–1227
- Fox, N.C., see Toombs, J. (3) 885–891
- Francis, P.T., see Chong, J.R. (1) 157–166
- Franz, C.E., see Granholm, E.L. (4) 1419–1428
- Fratiglioni, L., see Khan, W. (3) 1159–1174
- Frebourg, T., see Sellal, F. (1) 37–46
- Freund-Levi, Y., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Frisoni, G.B., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Frommann, I., see Polcher, A. (3) 1185–1196
- Frosch, M., see Sellal, F. (1) 37–46
- Frouin, V., see Khan, W. (3) 1159–1174
- Fujishima, M., A. Kawaguchi, N. Maikusa, R. Kuwano, T. Iwatsubo, H. Matsuda for the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI), Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging (1) 75–88
- Fülöp, T., see Castellano, C.-A. (4) 1459–1468
- Gafner, V., see Theunis, C. (2) 585–599
- Galimberti, D., see Ferrari, R. (4) 1271–1278
- Galimberti, D., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Gallagher, C.L., see Law, L.L. (1) 351–359
- Gallinat, J., see Khan, W. (3) 1159–1174
- Gamez, M., see Loewenstein, D.A. (3) 1119–1126
- Gapys, B., see Zyśk, M. (3) 1145–1158
- Garavan, H., see Khan, W. (3) 1159–1174
- García, E., see Gomez-Ramos, A. (3) 977–990
- Garcimartín, A., see González-Muñoz, M.J. (3) 917–927
- Gareri, P., A. Castagna, A.M. Cotroneo, D. Putignano, R. Conforti, F. Santamaría, S. Marino and S. Putignano, The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study (2) 557–565
- Garrido, P., see Gomez-Ramos, A. (3) 977–990
- Gasse, C., see Nørgaard, A. (2) 707–716
- Gaubert, M., N. Villain, B. Landeau, F. Mézenge, S. Egret, A. Perrotin, S. Belliard, V. de La Sayette, F. Eustache, B. Desgranges, G. Chételat and G. Rauchs, Neural Correlates of Self-Reference Effect in Early Alzheimer's Disease (2) 717–731
- Gauthier, S., see Ismail, Z. (3) 929–938
- Geda, Y.E., see Ismail, Z. (3) 929–938
- Gelfo, F., D. Cutuli, A. Nobili, P. De Bartolo, M. D'Amelio, L. Petrosini and C. Caltagirone, Chronic Lithium Treatment in a Rat Model of Basal Forebrain Cholinergic Depletion: Effects on Memory Impairment and Neurodegeneration (4) 1505–1518
- Genc, S., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Gertz, H.-J., see Sabbagh, M.N. (2) 441–446
- Ghidoni, R., see Benussi, L. (2) 825–833
- Ghidoni, R., see Ferrari, R. (4) 1271–1278
- Giaccone, G., see Ferrari, R. (4) 1271–1278
- Giakoumis, D., see Zygouris, S. (2) 619–627
- Giampietro, V., see Khan, W. (3) 1159–1174

- Gill, D.P., see Heath, M. (1) 167–183
- Gillen, D.L., see Grill, J.D. (3) 939–946
- Gimsing, L.N., see Thygesen, L.C. (4) 1429–1435
- Gispert, J.D., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Glozman, T., J. Solomon, F. Pestilli and L. Guibas, for the Alzheimer's Disease Neuroimaging Initiative, Shape-Attributes of Brain Structures as Biomarkers for Alzheimer's Disease (1) 287–295
- Goate, A.M., see Haddick, P.C.G. (3) 1037–1054
- Goff, M.L., see Pimouguet, C. (2) 509–517
- Gombert, C., see Sellal, F. (1) 37–46
- Gomez-Ramos, A., A.J. Picher, E. García, P. Garrido, F. Hernandez, E. Soriano and J. Avila, Validation of Suspected Somatic Single Nucleotide Variations in the Brain of Alzheimer's Disease Patients (3) 977–990
- Gong, Y., see Li, L. (4) 1403–1417
- González-Muñoz, M.J., A. Garcimartín, I. Meseguer, C.J. Mateos-Vega, J.M. Orellana, A. Peña-Fernández, J. Benedí and F.J. Sánchez-Muniz, Silicic Acid and Beer Consumption Reverses the Metal Imbalance and the Prooxidant Status Induced by Aluminum Nitrate in Mouse Brain (3) 917–927
- Gower, A.C., see Wang, E. (1) 47–61
- Gowland, P., see Khan, W. (3) 1159–1174
- Graff, C., see Li, X. (1) 327–334
- Graff-Radford, N., see N'Songo, A. (4) 1215–1222
- Graham, R.R., see Haddick, P.C.G. (3) 1037–1054
- Graham, S.J., see Hird, M.A. (2) 447–452
- Granholm, E.L., M.S. Panizzon, J.A. Elman, A.J. Jak, R.L. Hauger, M.W. Bondi, M.J. Lyons, C.E. Franz and W.S. Kremen, Pupillary Responses as a Biomarker of Early Risk for Alzheimer's Disease (4) 1419–1428
- Grant, P., see Shukla, V. (1) 335–349
- Grassi, M., see Ferrari, R. (4) 1271–1278
- Graziano, F., see Ferrari, R. (4) 1271–1278
- Greco, V., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Greenberg, S.M., see Sellal, F. (1) 37–46
- Greenberg, S.M., see Valenti, R. (4) 1223–1227
- Greig Custo, M.T., see N'Songo, A. (4) 1215–1222
- Grifols, J.R., see Boada, M. (1) 129–143
- Grignaschi, G., see Buccarello, L. (4) 1279–1292
- Grill, J.D., A. Holbrook, A. Pierce, D. Hoang and D.L. Gillen, Attitudes toward Potential Participant Registries (3) 939–946
- Grimm, M., see Brandscheid, C. (2) 775–788
- Grunstein, R.R., see McKinnon, A.C. (4) 1373–1384
- Guibas, L., see Glozman, T. (1) 287–295
- Gul-Hinc, S., see Zyśk, M. (3) 1145–1158
- Guo, Q., see Wang, Z. (1) 415–428
- Guo, Y., see Shen, L. (1) 361–378
- Guo, Y.-C., see Wang, Q. (4) 1525–1539
- Gurol, M.E., see Valenti, R. (4) 1223–1227
- Ha, A.Y., see Lee, H.-K. (3) 1015–1036
- Haddick, P.C.G., J.L. Larson, N. Rathore, T.R. Bhangale, Q.T. Phung, K. Srinivasan, D.V. Hansen, J.R. Lill, Alzheimer's Disease Genetic Consortium (ADGC), Alzheimer's Disease Neuroimaging Initiative (ADNI), M.A. Pericak-Vance, J. Haines, L.A. Farrer, J.S. Kauwe, G.D. Schellenberg, C. Cruchaga, A.M. Goate, T.W. Behrens, R.J. Watts, R.R. Graham, J.S. Kaminker and M. van der Brug, A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer's Disease Brains (3) 1037–1054
- Haines, J., see Haddick, P.C.G. (3) 1037–1054
- Hall, A., see Suhonen, N.-M. (4) 1241–1251
- Hallikainen, I., see Suhonen, N.-M. (4) 1241–1251
- Ham, L.S., see Meijboom, R. (2) 789–804
- Hampel, H., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Han, F.-F., see Wang, Q. (4) 1525–1539
- Hannequin, D., see Sellal, F. (1) 37–46
- Hänninen, T., see Suhonen, N.-M. (4) 1241–1251
- Hansen, D.V., see Haddick, P.C.G. (3) 1037–1054
- Hansen, E.S., see Nørgaard, A. (2) 707–716
- Hao, K., see Ho, L. (1) 305–315
- Hardy, J., see Ferrari, R. (4) 1271–1278
- Hariramani, R., see Matías-Guiu, J.A. (2) 733–742
- Hartikainen, S., see Koponen, M. (1) 107–118
- Hartikainen, S., see Lampela, P. (1) 119–128
- Hartmann, T., see Brandscheid, C. (2) 775–788
- Hashimoto, Y., see Kamikubo, Y. (2) 641–653
- Hattori, N., see Jurjević, I. (1) 317–325
- Hauger, R.L., see Granholm, E.L. (4) 1419–1428
- He, Y., see Wang, Z. (1) 415–428
- Head, E., see Doran, E. (2) 459–470
- Heath, M., E. Shellington, S. Titheridge, D.P. Gill and R.J. Petrella, A 24-Week Multi-Modality Exercise Program Improves Executive Control in Older Adults with a Self-Reported Cognitive Complaint: Evidence from the Antisaccade Task (1) 167–183
- Heinz, A., see Khan, W. (3) 1159–1174
- Heisz, J.J., see Fenesi, B. (1) 297–303
- Helmer, C., see Pimouguet, C. (2) 509–517
- Hemmy, L.S., see Liu, P. (2) 743–761

- Hermann, B.P., see Law, L.L. (1) 351–359
- Hernandez, F., see Gomez-Ramos, A. (3) 977–990
- Hernández, I., see Boada, M. (1) 129–143
- Herrmann, N., see Ismail, Z. (3) 929–938
- Herukka, S.-K., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Heslegrave, A., see Toombs, J. (3) 885–891
- Hickie, I.B., see McKinnon, A.C. (4) 1373–1384
- Hickman, D.T., see Theunis, C. (2) 585–599
- Hietanen, M., see Kallio, E.-L. (4) 1349–1372
- Hird, M.A., K.A. Vesely, C.E. Fischer, S.J. Graham, G. Naglie and T.A. Schweizer, Investigating Simulated Driving Errors in Amnestic Single- and Multiple-Domain Mild Cognitive Impairment (2) 447–452
- Hisatsune, T., see Matsuda, T. (1) 1–23
- Ho, L., M. Legere, T. Li, S. Levine, K. Hao, B. Valcarcel and G.M. Pasinetti, Autonomic Nervous System Dysfunctions as a Basis for a Predictive Model of Risk of Neurological Disorders in Subjects with Prior History of Traumatic Brain Injury: Implications in Alzheimer's Disease (1) 305–315
- Hoang, D., see Grill, J.D. (3) 939–946
- Hodges, J.R., see Kaizik, C. (3) 1109–1117
- Hofmann-Apitius, M., see Emon, M.A.E.K. (2) 677–686
- Holbrook, A., see Grill, J.D. (3) 939–946
- Holstege, H., see Louwersheimer, E. (1) 63–74
- Hong, C.H., see Chang, K.J. (4) 1341–1348
- Hong, X., see Wang, H. (3) 875–883
- Horváth, A., A. Szűcs, G. Barcs and A. Kamondi, Sleep EEG Detects Epileptiform Activity in Alzheimer's Disease with High Sensitivity (3) 1175–1183
- Howlett, D., see Chong, J.R. (1) 157–166
- Hsieh-Li, H.-M., see Lin, T.-S. (3) 959–976
- Hu, C., J. Xu, L. Zeng, T. Li, M.-Z. Cui and X. Xu, Pen-2 and Presenilin are Sufficient to Catalyze Notch Processing (4) 1263–1269
- Huang, E.S., see Liu, P. (2) 743–761
- Huang, J.-F., see Wang, Q. (4) 1525–1539
- Huang, R.-S., see Lin, T.-S. (3) 959–976
- Huang, S.-C., ses Ferrari, L. (3) 1101–1107
- Hulsman, M., see Louwersheimer, E. (1) 63–74
- Hvidt, N.C., see Thygesen, L.C. (4) 1429–1435
- Ienca, M., J. Fabrice, B. Elger, M. Caon, A.S. Pappagallo, R.W. Kressig and T. Wangmo, Intelligent Assistive Technology for Alzheimer's Disease and Other Dementias: A Systematic Review (4) 1301–1340
- Igel, H.J., see Apostolova, I. (1) 197–204
- Ihara, M., see Kuriyama, N. (4) 1253–1262
- Ikram, U., see Agyemang, C. (1) 205–213
- Imbeault, H., see Castellano, C.-A. (4) 1459–1468
- Imtiaz, B., A.M. Tolppanen, A. Solomon, H. Soininen and M. Kivipelto, Estradiol and Cognition in the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) Cohort Study (2) 453–458
- Innes, K.E., T.K. Selfe, D.S. Khalsa and S. Kandati, Meditation and Music Improve Memory and Cognitive Function in Adults with Subjective Cognitive Decline: A Pilot Randomized Controlled Trial (3) 899–916
- Iqbal, K., see Baazaoui, N. (4) 1385–1401
- Ismail, Z., L. Agüera-Ortiz, H. Brodaty, A. Cieslak, J. Cummings, C.E. Fischer, S. Gauthier, Y.E. Geda, N. Herrmann, J. Kanji, K.L. Lanctôt, D.S. Miller, M.E. Mortby, C.U. Onyike, P.B. Rosenberg, E.E. Smith, G.S. Smith, D.L. Sultzer and C. Lyketsos for the NPS Professional Interest Area of the International Society of to Advance Alzheimer's Research and Treatment (NPS-PIA of ISTAART), The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations (3) 929–938
- Itamura, K., see Lee, H.-K. (3) 1015–1036
- Ittermann, B., see Khan, W. (3) 1159–1174
- Iwata, N., see Matsunaga, S. (4) 1229–1239
- Iwatsubo, T., see Fujishima, M. (1) 75–88
- Jacob, L., J. Bohlken and K. Kostev, Prevalence of Use of Cardiovascular Drugs in Dementia Patients Treated in General Practices in Germany (4) 1519–1524
- Jacob, L., J. Bohlken and K. Kostev, Risk Factors for Mild Cognitive Impairment in German Primary Care Practices (1) 379–384
- Jacobs, T., see Borghys, H. (2) 763–774
- Jak, A.J., see Granholm, E.L. (4) 1419–1428
- James, B.D., see Yarchoan, M. (2) 699–706
- Jaul, E. and O. Meiron, Dementia and Pressure Ulcers: Is There a Close Pathophysiological Interrelation? (3) 861–866
- Jensen-Dahm, C., see Nørgaard, A. (2) 707–716
- Jessen, F., see Polcher, A. (3) 1185–1196
- Ji, H.-F., see Shen, L. (1) 385–390
- Jia, J., C. Wei, L. Jia, Y. Tang, J. Liang, A. Zhou, F. Li, L. Shi and R.S. Doody, Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial (4) 1495–1504

- Jia, J., see Wu, L. (3) 893–898  
 Jia, L., see Jia, J. (4) 1495–1504  
 Jiang, L., see Xie, B. (1) 391–401  
 Jiang, Y., see Tan, L. (2) 629–640  
 Johansen, C., see Thygesen, L.C. (4) 1429–1435  
 Johnson, S.C., see Law, L.L. (1) 351–359  
 Jokelainen, J., see Suhonen, N.-M. (4) 1241–1251  
 Jones, L., see Morgan, A.R. (1) 25–36  
 Jongbloed, W., see Slot, R.E.R. (2) 687–697  
 Jorandby, L., see Amen, D.G. (1) 261–273  
 Jovalekic, A., see Sabbagh, M.N. (2) 441–446  
 Jurjević, I., M. Miyajima, I. Ogino, C. Akiba, M. Nakajima, A. Kondo, M. Kikkawa, M. Kanai, N. Hattori and H. Arai, Decreased Expression of hsa-miR-4274 in Cerebrospinal Fluid of Normal Pressure Hydrocephalus Mimics with Parkinsonian Syndromes (1) 317–325
- Kaddoumi, A., see Mohamed, L.A. (3) 1087–1099  
 Kaizik, C., J. Caga, J. Camino, C.M. O'Connor, C. McKinnon, J.R. Oyebode, O. Piguet, J.R. Hodges and E. Mioshi, Factors Underpinning Caregiver Burden in Frontotemporal Dementia Differ in Spouses and their Children (3) 1109–1117  
 Kallio, E.-L., H. Öhman, H. Kautiainen, M. Hietanen and K. Pitkälä, Cognitive Training Interventions for Patients with Alzheimer's Disease: A Systematic Review (4) 1349–1372  
 Kalpouzos, G., see Khan, W. (3) 1159–1174  
 Kamikubo, Y., N. Takasugi, K. Niisato, Y. Hashimoto and T. Sakurai, Consecutive Analysis of BACE1 Function on Developing and Developed Neuronal Cells (2) 641–653  
 Kaminker, J.S., see Haddick, P.C.G. (3) 1037–1054  
 Kamondi, A., see Horváth, A. (3) 1175–1183  
 Kanai, M., see Jurjević, I. (1) 317–325  
 Kandati, S., see Innes, K.E. (3) 899–916  
 Kang, D.R., see Chang, K.J. (4) 1341–1348  
 Kanji, J., see Ismail, Z. (3) 929–938  
 Karagiannidis, C., see Zygouris, S. (2) 619–627  
 Karki, R., see Emon, M.A.E.K. (2) 677–686  
 Kautiainen, H., see Kallio, E.-L. (4) 1349–1372  
 Kauwe, J.S., see Haddick, P.C.G. (3) 1037–1054  
 Kawaguchi, A., see Fujishima, M. (1) 75–88  
 Keator, D., see Doran, E. (2) 459–470  
 Kesavapany, S., see Shukla, V. (1) 335–349  
 Kester, M.I., see Slot, R.E.R. (2) 687–697  
 Khalsa, D.S., see Innes, K.E. (3) 899–916  
 Khan, W., V. Giampietro, T. Banaschewski, G.J. Barker, A.L.W. Bokde, C. Büchel, P. Conrod, H. Flor, V. Frouin, H. Garavan, P. Gowland, A. Heinz, B. Ittermann, H. Lemaitre, F. Nees, T. Paus, Z. Pausova, M. Rietschel, M.N. Smolka, A. Ströhle, J. Gallinat, B. Vellas, H. Soininen, I. Kloszewska, M. Tsolaki, P. Mecocci, C. Spenger, V.L. Villemagne, C.L. Masters, J.-S. Muehlboeck, L. Bäckman, L. Fratiglioni, G. Kalpouzos, L.-O. Wahlund, G. Schumann, S. Lovestone, S.C.R. Williams, E. Westman, A. Simmons, Alzheimer's Disease Neuroimaging Initiative, AddNeuroMed Consortium, Australian Imaging, Biomarkers, and Lifestyle Study Research Group and the IMAGEN consortium, A Multi-Cohort Study of ApoE ε4 and Amyloid-β Effects on the Hippocampus in Alzheimer's Disease (3) 1159–1174  
 Khami, F., see Zerah, L. (1) 145–156  
 Kikkawa, M., see Jurjević, I. (1) 317–325  
 Kim, B., see Kim, Y.J. (3) 1007–1014  
 Kim, D.-K., see Chang, K.J. (4) 1341–1348  
 Kim, K.W., see Kim, Y.J. (3) 1007–1014  
 Kim, R., see Doran, E. (2) 459–470  
 Kim, S.Y., see Chang, K.J. (4) 1341–1348  
 Kim, Y.J., H. An, B. Kim, Y.S. Park and K.W. Kim, An International Comparative Study on Driving Regulations on People with Dementia (3) 1007–1014  
 Kishi, T., see Matsunaga, S. (4) 1229–1239  
 Kivipelto, M., see Imtiaz, B. (2) 453–458  
 Kliper, E., see Molad, J. (4) 1293–1299  
 Kloszewska, I., see Khan, W. (3) 1159–1174  
 Kodali, R., see Fitz, N.F. (3) 1075–1085  
 Kodamullil, A.T., see Emon, M.A.E.K. (2) 677–686  
 Koek, H.L., see Agyemang, C. (1) 205–213  
 Koene, T., see Louwersheimer, E. (1) 63–74  
 Koene, T., see Van Mierlo, L.D. (1) 249–259  
 Koldamova, R., see Fitz, N.F. (3) 1075–1085  
 Kondo, A., see Jurjević, I. (1) 317–325  
 Kondo, M., see Kuriyama, N. (4) 1253–1262  
 Koponen, M., H. Taipale, P. Lavikainen, A. Tanskanen, J. Tiihonen, A.-M. Tolppanen, R. Ahonen and S. Hartikainen, Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer's Disease (1) 107–118  
 Koppara, A., see Polcher, A. (3) 1185–1196  
 Korcarz, C.E., see Law, L.L. (1) 351–359  
 Korczyn, A.D., see Molad, J. (4) 1293–1299  
 Koscik, R.L., see Law, L.L. (1) 351–359  
 Kostev, K., see Jacob, L. (1) 379–384  
 Kostev, K., see Jacob, L. (4) 1519–1524

- Kotani, R., Y. Urano, H. Sugimoto and N. Noguchi, Decrease of Amyloid- $\beta$  Levels by Curcumin Derivative via Modulation of Amyloid- $\beta$  Protein Precursor Trafficking (2) 529–542
- Kourkoulis, C.E., see Sellal, F. (1) 37–46
- Kovacevic, A., see Fenesi, B. (1) 297–303
- Kowall, N., see Wang, E. (1) 47–61
- Koyama, T., see Kuriyama, N. (4) 1253–1262
- Kremen, W.S., see Granholm, E.L. (4) 1419–1428
- Kressig, R.W., see Ienca, M. (4) 1301–1340
- Krüger, J., see Suhonen, N.-M. (4) 1241–1251
- Kuijf, H.J., see Valenti, R. (4) 1223–1227
- Kuiperij, H.B., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Kuntz, S., see Shukla, V. (1) 335–349
- Kunz, L., M. Reuter, N. Axmacher and C. Montag, Conscientiousness is Negatively Associated with Grey Matter Volume in Young APOE  $\epsilon$ 4-Carriers (3) 1135–1144
- Kuriyama, N., M. Ihara, T. Mizuno, E. Ozaki, D. Matsui, I. Watanabe, T. Koyama, M. Kondo, T. Tokuda, A. Tamura, K. Yamada, K. Akazawa, K. Takeda, A. Takada, S. Mizuno, M. Nakagawa and Y. Watanabe, Association between Mid-Regional Preadrenomedullin Levels and Progression of Deep White Matter Lesions in the Brain Accompanying Cognitive Decline (4) 1253–1262
- Kuskowski, M.A., see Liu, P. (2) 743–761
- Kuwano, R., see Fujishima, M. (1) 75–88
- Kwon, B., see Lee, H.-K. (3) 1015–1036
- Lacombe, G., see Castellano, C.-A. (4) 1459–1468
- Lafuente, A., see Boada, M. (1) 129–143
- Lagopoulos, J., see McKinnon, A.C. (4) 1373–1384
- Lai, M.K.P., see Chong, J.R. (1) 157–166
- Lämmler, G., see Apostolova, I. (1) 197–204
- Lampela, P., A.-M. Tolppanen, A. Tanskanen, J. Tiilinen, S. Hartikainen and H. Taipale, Anticholinergic Exposure and Risk of Pneumonia in Persons with Alzheimer's Disease: A Nested Case-Control Study (1) 119–128
- Lanctôt, K.L., see Ismail, Z. (3) 929–938
- Landau, S., see Sundermann, E.E. (3) 947–957
- Landeau, B., see Gaubert, M. (2) 717–731
- Lange, C., see Apostolova, I. (1) 197–204
- Langlois, F., see Castellano, C.-A. (4) 1459–1468
- Larsen, A.I., see Bergland, A.K. (2) 575–584
- Larson, J.L., see Haddick, P.C.G. (3) 1037–1054
- Last, N., E. Tufts and L.E. Auger, The Effects of Meditation on Grey Matter Atrophy and Neurodegeneration: A Systematic Review (1) 275–286
- Lattanzio, F., see Persson, T. (2) 601–617
- Lavikainen, P., see Koponen, M. (1) 107–118
- Law, L.L., S.A. Schultz, E.A. Boots, J.A. Einerson, R.J. Dougherty, J.M. Oh, C.E. Korcarz, D.F. Edwards, R.L. Kosciuk, N.M. Dowling, C.L. Gallagher, B.B. Bendlin, C.M. Carlsson, S. Asthana, B.P. Hermann, M.A. Sager, S.C. Johnson, D.B. Cook, J.H. Stein and O.C. Okonkwo, Chronotropic Response and Cognitive Function in a Cohort at Risk for Alzheimer's Disease (1) 351–359
- Lee, C.-H., see Lin, T.-S. (3) 959–976
- Lee, H.-K., B. Kwon, C.A. Lemere, S. de la Monte, K. Itamura, A.Y. Ha and H.W. Querfurth, mTORC2 (Rictor) in Alzheimer's Disease and Reversal of Amyloid- $\beta$  Expression-Induced Insulin Resistance and Toxicity in Rat Primary Cortical Neurons (3) 1015–1036
- Lee, J.D., see Chang, K.J. (4) 1341–1348
- Lee, J.H., see Chong, J.R. (1) 157–166
- Lee, K.S., see Chang, K.J. (4) 1341–1348
- Lee, Y., see Chang, K.J. (4) 1341–1348
- Lefterov, I., see Fitz, N.F. (3) 1075–1085
- Legere, M., see Ho, L. (1) 305–315
- Lei, P., see Betrie, A.H. (2) 849–860
- Lemaître, H., see Khan, W. (3) 1159–1174
- Lemere, C.A., see Lee, H.-K. (3) 1015–1036
- Leocani, L., see Ferrari, L. (3) 1101–1107
- Lethias, C., see Salza, R. (3) 991–1005
- Levine, S., see Ho, L. (1) 305–315
- Lewis, S.J.G., see McKinnon, A.C. (4) 1373–1384
- Li, F., see Jia, J. (4) 1495–1504
- Li, G.-H., see Wang, Q. (4) 1525–1539
- Li, H., see Tan, L. (2) 629–640
- Li, J., see Li, L. (4) 1403–1417
- Li, J., see Wu, L. (3) 893–898
- Li, L., S. Xu, L. Liu, R. Feng, Y. Gong, X. Zhao, J. Li, J. Cai, N. Feng, L. Wang, X. Wang and Y. Peng, Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF- $\alpha$  and IL-1 $\beta$  in an  $A\beta_{25-35}$ -induced Rat Model of Alzheimer's Disease (4) 1403–1417
- Li, S., see Shen, L. (1) 361–378
- Li, T., see Ho, L. (1) 305–315
- Li, T., see Hu, C. (4) 1263–1269
- Li, W.-X., see Wang, Q. (4) 1525–1539
- Li, X., E. Westman, S. Thordardottir, A.K. Ståhlbom, O. Almkvist, K. Blennow, L.-O. Wahlund and

- C. Graff, The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer's Disease (1) 327–334
- Li, X., see Sokolow, S. (1) 229–237
- Liang, J., see Jia, J. (4) 1495–1504
- Liang, M.-C., see Lin, T.-S. (3) 959–976
- Liao, L., see Shen, L. (1) 361–378
- Liese, S., see Apostolova, I. (1) 197–204
- Lill, J.R., see Haddick, P.C.G. (3) 1037–1054
- Lim, K.Y., see Chang, K.J. (4) 1341–1348
- Lin, T.-S., H.-J. Tsai, C.-H. Lee, Y.-Q. Song, R.-S. Huang, H.-M. Hsieh-Li, M.-C. Liang and Y. Lin, An Improved Drugs Screening System Reveals that Baicalein Ameliorates the A $\beta$ /AMPA/NMDA-Induced Depolarization of Neurons (3) 959–976
- Lin, Y., see Lin, T.-S. (3) 959–976
- Lipton, R.B., see Sundermann, E.E. (3) 947–957
- Liu, D., see Wang, Z. (1) 415–428
- Liu, J., see Wu, L. (3) 893–898
- Liu, L., see Li, L. (4) 1403–1417
- Liu, L., see Shen, L. (1) 385–390
- Liu, P., J.H. Reichl, E.R. Rao, B.M. McNellis, E.S. Huang, L.S. Hemmy, C.L. Forster, M.A. Kuskowski, D.R. Borchelt, R. Vassar, K.H. Ashe and K.R. Zahs, Quantitative Comparison of Dense-Core Amyloid Plaque Accumulation in Amyloid- $\beta$  Protein Precursor Transgenic Mice (2) 743–761
- Liu, Q., see Shen, L. (1) 361–378
- Liu, W., see Tan, L. (2) 629–640
- Liu, W., see Xie, B. (1) 391–401
- Liu, Y., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Liu, Z., see Xie, B. (1) 391–401
- Lladó, A., see Tell-Martí, G. (3) 1065–1074
- Lladó, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Lleó, A., see Tell-Martí, G. (3) 1065–1074
- Lleó, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Loewenstein, D.A., R.E. Curiel, C. Wright, X. Sun, N. Alperin, E. Crocco, S.J. Czaja, A. Raffo, A. Penate, J. Melo, K. Capp, M. Gamez and R. Duara, Recovery from Proactive Semantic Interference in Mild Cognitive Impairment and Normal Aging: Relationship to Atrophy in Brain Regions Vulnerable to Alzheimer's Disease (3) 1119–1126
- Loewenstein, D.A., see Matías-Guiu, J.A. (2) 733–742
- Longo, A., see Boccardi, V. (1) 239–248
- Lopez, O.L., see Boada, M. (1) 129–143
- Lott, I.T., see Doran, E. (2) 459–470
- Louwersheimer, E., P.E. Cohn-Hokke, Y.A.L. Pijnenburg, M.M. Weiss, E.A. Sistermans, A.J. Rozemuller, M. Hulsman, J.C. van Swieten, C.M. van Duijn, F. Barkhof, T. Koene, P. Scheltens, W.M. Van der Flier and H. Holstege, Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE- $\epsilon$ 4 Homozygosity (1) 63–74
- Lovestone, S., see Khan, W. (3) 1159–1174
- Lu, X., see Chen, J. (2) 471–489
- Lu, Y., Y. Dong, D. Tucker, R. Wang, M.E. Ahmed, D. Brann and Q. Zhang, Treadmill Exercise Exerts Neuroprotection and Regulates Microglial Polarization and Oxidative Stress in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease (4) 1469–1484
- Lunn, M.P., see Toombs, J. (3) 885–891
- Lyketsos, C., see Ismail, Z. (3) 929–938
- Lyons, M.J., see Granholm, E.L. (4) 1419–1428
- Magnani, G., see Ferrari, L. (3) 1101–1107
- Maikusa, N., see Fujishima, M. (1) 75–88
- Maioli, S., see Persson, T. (2) 601–617
- Majounie, E., see Morgan, A.R. (1) 25–36
- Maki, P.M., see Sundermann, E.E. (3) 947–957
- Maletta, R.G., see Ferrari, R. (4) 1271–1278
- Manavis, J., see Chidlow, G. (2) 655–675
- Manzo, V., see Carotenuto, A. (2) 805–815
- Marelli, C., see Sellal, F. (1) 37–46
- Marino, S., see Gareri, P. (2) 557–565
- Marmarelis, V.Z., D.C. Shin, T. Tarumi and R. Zhang, Comparison of Model-Based Indices of Cerebral Autoregulation and Vasomotor Reactivity Using Transcranial Doppler versus Near-Infrared Spectroscopy in Patients with Amnestic Mild Cognitive Impairment (1) 89–105
- Martinez-Almoyna, L., see Sellal, F. (1) 37–46
- Martins, R.N., see Peters, K.E. (3) 1127–1133
- Masters, C.L., see Khan, W. (3) 1159–1174
- Masters, C.L., see Peters, K.E. (3) 1127–1133
- Masters, C.L., see Sabbagh, M.N. (2) 441–446
- Mateos-Vega, C.J., see González-Muñoz, M.J. (3) 917–927
- Matías-Guiu, J., see Matías-Guiu, J.A. (2) 733–742
- Matías-Guiu, J.A., R.E. Curiel, T. Rognoni, M. Valles-Salgado, M. Fernández-Matarrubia, R.

- Hariramani, A. Fernández-Castro, T. Moreno-Ramos, D.A. Loewenstein and J. Matías-Guiu, Validation of the Spanish Version of the LASSI-L for Diagnosing Mild Cognitive Impairment and Alzheimer's Disease (2) 733–742
- Matsuda, H., see Fujishima, M. (1) 75–88
- Matsuda, T. and T. Hisatsune, Cholinergic Modification of Neurogenesis and Gliosis Improves the Memory of A $\beta$ PPswe/PSEN1dE9 Alzheimer's Disease Model Mice Fed a High-Fat Diet (1) 1–23
- Matsui, D., see Kuriyama, N. (4) 1253–1262
- Matsunaga, S., T. Kishi and N. Iwata, Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis (4) 1229–1239
- Matte, J.J., see Castellano, C.-A. (4) 1459–1468
- Mäurer, A., see Apostolova, I. (1) 197–204
- McKinnon, A.C., S.L. Duffy, N.E. Cross, Z. Terpening, R.R. Grunstein, J. Lagopoulos, J. Batchelor, I.B. Hickie, S.J.G. Lewis, J.M. Shine and S.L. Naismith, Functional Connectivity in the Default Mode Network is Reduced in Association with Nocturnal Awakening in Mild Cognitive Impairment (4) 1373–1384
- McKinnon, C., see Kaizik, C. (3) 1109–1117
- McLiman, K.E., A.A. Willette and for the Alzheimer's Disease Neuroimaging Initiative, Autotaxin is Related to Metabolic Dysfunction and Predicts Alzheimer's Disease Outcomes (1) 403–413
- McNellis, B.M., see Liu, P. (2) 743–761
- Mecocci, P., see Boccardi, V. (1) 239–248
- Mecocci, P., see Khan, W. (3) 1159–1174
- Meijboom, R., R.M.E. Steketee, L.S. Ham, A. van der Lugt, J.C. van Swieten and M. Smits, Differential Hemispheric Predilection of Microstructural White Matter and Functional Connectivity Abnormalities between Respectively Semantic and Behavioral Variant Frontotemporal Dementia (2) 789–804
- Meiron, O., see Jaul, E. (3) 861–866
- Melcangi, R.C., see Buccarello, L. (4) 1279–1292
- Melo, J., see Loewenstein, D.A. (3) 1119–1126
- Mendez, A.J., see Squitti, R. (3) 1055–1064
- Mercken, M., see Timmers, M. (4) 1437–1449
- Meseguer, I., see González-Muñoz, M.J. (3) 917–927
- Meulenbroek, O., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Meysami, S., see Amen, D.G. (1) 261–273
- Mézenge, F., see Gaubert, M. (2) 717–731
- Meziere, A., see Zerah, L. (1) 145–156
- Migliore, L., see Stoccoro, A. (4) 1451–1457
- Miller, D.S., see Ismail, Z. (3) 929–938
- Miné, M., see Sellal, F. (1) 37–46
- Mioshi, E., see Kaizik, C. (3) 1109–1117
- Mishra, S.K., see Shukla, V. (1) 335–349
- Miyajima, M., see Jurjević, I. (1) 317–325
- Mizuno, S., see Kuriyama, N. (4) 1253–1262
- Mizuno, T., see Kuriyama, N. (4) 1253–1262
- Moechars, D., see Timmers, M. (4) 1437–1449
- Mohamed, L.A., H. Zhu, Y.M. Mousa, E. Wang, W.Q. Qiu and A. Kaddoumi, Amylin Enhances Amyloid- $\beta$  Peptide Brain to Blood Efflux Across the Blood-Brain Barrier (3) 1087–1099
- Molad, J., E. Kliper, A.D. Korczyn, E. Ben Assayag, D. Ben Bashat, S. Shenhar-Tsarfaty, O. Aizenstein, L. Shopin, N.M. Bornstein and E. Auriel, Only White Matter Hyperintensities Predicts Post-Stroke Cognitive Performances Among Cerebral Small Vessel Disease Markers: Results from the TABASCO Study (4) 1293–1299
- Molinuevo, J.L., see Tell-Martí, G. (3) 1065–1074
- Molinuevo, J.L., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Momeni, P., see Ferrari, R. (4) 1271–1278
- Monacelli, F., A. Signori, L. Roffredo, K. Pace, A. Nencioni, G. Pickering, M. Nicolas and P. Odetti, Algoplus® Scale in Older Patients with Dementia: A Reliable Real-World Pain Assessment Tool (2) 519–527
- Montag, C., see Kunz, L. (3) 1135–1144
- Moreno-Ramos, T., see Matías-Guiu, J.A. (2) 733–742
- Morgan, A.R., S. Touchard, C. O'Hagan, R. Sims, E. Majounie, V. Escott-Price, L. Jones, J. Williams and B.P. Morgan, The Correlation between Inflammatory Biomarkers and Polygenic Risk Score in Alzheimer's Disease (1) 25–36
- Morgan, B.P., see Morgan, A.R. (1) 25–36
- Mortby, M.E., see Ismail, Z. (3) 929–938
- Mousa, Y.M., see Mohamed, L.A. (3) 1087–1099
- Muehlboeck, J.-S., see Khan, W. (3) 1159–1174
- Muhs, A., see Theunis, C. (2) 585–599
- Muñoz, J., see Boada, M. (1) 129–143
- Murata, S., see Sugimoto, T. (2) 567–574
- Murayama, S., see Sabbagh, M.N. (2) 441–446
- N'Songo, A., M.M. Carrasquillo, X. Wang, T. Nguyen, Y. Asmann, S.G. Younkin, M. Allen, R. Duara, M.T. Greig Custo, N. Graff-Radford and N. Ertekin-Taner, Comprehensive Screening for Disease Risk Variants in Early-

- Onset Alzheimer's Disease Genes in African Americans Identifies Novel PSEN Variants (4) 1215–1222
- Na, D.L., see Chang, K.J. (4) 1341–1348
- Nacmias, B., see Ferrari, R. (4) 1271–1278
- Nacmias, B., see Stoccoro, A. (4) 1451–1457
- Naglie, G., see Hird, M.A. (2) 447–452
- Naismith, S.L., see McKinnon, A.C. (4) 1373–1384
- Nakagawa, M., see Kuriyama, N. (4) 1253–1262
- Nakajima, M., see Jurjević, I. (1) 317–325
- Nakanishi, M., J. Niimura, S. Yamasaki and A. Nishida, Death of Dementia Patients in Psychiatric Hospitals and Regional Supply of Psychiatric Services: Study of the National Data from 1996 to 2014 in Japan (2) 817–824
- Nees, F., see Khan, W. (3) 1159–1174
- Nencioni, A., see Monacelli, F. (2) 519–527
- Neri, C., see Zerah, L. (1) 145–156
- Nguyen, T., see N'Songo, A. (4) 1215–1222
- Ni, J., see Shen, L. (1) 361–378
- Nicolas, G., see Sellal, F. (1) 37–46
- Nicolas, M., see Monacelli, F. (2) 519–527
- Niida, S., see Sugimoto, T. (2) 567–574
- Niimura, J., see Nakanishi, M. (2) 817–824
- Niisato, K., see Kamikubo, Y. (2) 641–653
- Nishida, A., see Nakanishi, M. (2) 817–824
- Nobili, A., see Gelfo, F. (4) 1505–1518
- Nobili, F.M., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Noguchi, N., see Kotani, R. (2) 529–542
- Noh, J.S., see Chang, K.J. (4) 1341–1348
- Nørgaard, A., C. Jensen-Dahm, C. Gasse, E.S. Hansen and G. Waldemar, Psychotropic Polypharmacy in Patients with Dementia: Prevalence and Predictors (2) 707–716
- Norredam, M., see Agyemang, C. (1) 205–213
- Ntovas, K., see Zygouris, S. (2) 619–627
- Núñez, L., see Boada, M. (1) 129–143
- O'Connor, C.M., see Kaizik, C. (3) 1109–1117
- O'Hagan, C., see Morgan, A.R. (1) 25–36
- Obisesan, T.O., see Boada, M. (1) 129–143
- Odetti, P., see Monacelli, F. (2) 519–527
- Oesterlé, H., see Sellal, F. (1) 37–46
- Ogino, I., see Jurjević, I. (1) 317–325
- Oguz, K.K., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Oh, J.M., see Law, L.L. (1) 351–359
- Öhman, H., see Kallio, E.-L. (4) 1349–1372
- Okonkwo, O.C., see Law, L.L. (1) 351–359
- Olazarán, J., see Boada, M. (1) 129–143
- Ono, R., see Sugimoto, T. (2) 567–574
- Onyike, C.U., see Ismail, Z. (3) 929–938
- Orellana, J.M., see González-Muñoz, M.J. (3) 917–927
- Oremus, M., see Fenesi, B. (1) 297–303
- Ormaechea, J.F., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Ortiz, P., see Boada, M. (1) 129–143
- Ostrowski, T.D., see Ebel, D.L. (3) 1197–1211
- Oyebode, J.R., see Kaizik, C. (3) 1109–1117
- Ozaki, E., see Kuriyama, N. (4) 1253–1262
- Pace, K., see Monacelli, F. (2) 519–527
- Padovani, A., see Ferrari, R. (4) 1271–1278
- Páez, A., see Boada, M. (1) 129–143
- Palluzzi, F., see Ferrari, R. (4) 1271–1278
- Pang, W., see Tan, L. (2) 629–640
- Panizzon, M.S., see Granholm, E.L. (4) 1419–1428
- Pant, H.C., see Shukla, V. (1) 335–349
- Pantoni, L., see Valenti, R. (4) 1223–1227
- Pappagallo, A.S., see Ienca, M. (4) 1301–1340
- Paquet, N., see Castellano, C.-A. (4) 1459–1468
- Park, J., see Chang, K.J. (4) 1341–1348
- Park, Y.S., see Kim, Y.J. (3) 1007–1014
- Parnetti, L., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Pasinetti, G.M., see Ho, L. (1) 305–315
- Paterson, R.W., see Toombs, J. (3) 885–891
- Paus, T., see Khan, W. (3) 1159–1174
- Pausova, Z., see Khan, W. (3) 1159–1174
- Peña-Fernández, A., see González-Muñoz, M.J. (3) 917–927
- Penate, A., see Loewenstein, D.A. (3) 1119–1126
- Peng, Y., see Li, L. (4) 1403–1417
- Pereira, J., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Pericak-Vance, M.A., see Haddick, P.C.G. (3) 1037–1054
- Perrotin, A., see Gaubert, M. (2) 717–731
- Persson, T., F. Lattanzio, J. Calvo-Garrido, R. Rimondini, M. Rubio-Rodrigo, E. Sundström, S. Maioli, A. Sandebring-Matton and Á. Cedazo-Mínguez, Apolipoprotein E4 Elicits Lysosomal Cathepsin D Release, Decreased Thioredoxin-1 Levels, and Apoptosis (2) 601–617
- Pestilli, F., see Glözman, T. (1) 287–295
- Peters, K.E., W.A. Davis, K. Taddei, R.N. Martins, C.L. Masters, T.M.E. Davis and D.G. Bruce, Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study (3) 1127–1133
- Peters, O., see Sabbagh, M.N. (2) 441–446
- Peters, R., see Anstey, K.J. (1) 215–228
- Petrella, R.J., see Heath, M. (1) 167–183

- Petrosini, L., see Gelfo, F. (4) 1505–1518
- Pfeifer, A., see Theunis, C. (2) 585–599
- Phelan, M.J., see Doran, E. (2) 459–470
- Phung, Q.T., see Haddick, P.C.G. (3) 1037–1054
- Piaceri, I., see Ferrari, R. (4) 1271–1278
- Piaz, F.D., see Benussi, L. (2) 825–833
- Picco, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Picher, A.J., see Gomez-Ramos, A. (3) 977–990
- Pickering, G., see Monacelli, F. (2) 519–527
- Pierce, A., see Grill, J.D. (3) 939–946
- Pietrzik, C.U., see Brandscheid, C. (2) 775–788
- Piguet, O., see Kaizik, C. (3) 1109–1117
- Pihlgren, M., see Theunis, C. (2) 585–599
- Pijnenburg, Y.A.L., see Louwersheimer, E. (1) 63–74
- Pikkarainen, M., see Suhonen, N.-M. (4) 1241–1251
- Pikkarainen, M., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Pimouquet, C., M.L. Goff, J. Wittwer, J.-F. Dartigues and C. Helmer, Benefits of Occupational Therapy in Dementia Patients: Findings from a Real-World Observational Study (2) 509–517
- Pinessi, L., see Ferrari, R. (4) 1271–1278
- Piorkowska, K., see Theunis, C. (2) 585–599
- Pitkälä, K., see Kallio, E.-L. (4) 1349–1372
- Plana, E., see Tell-Marti, G. (3) 1065–1074
- Polcher, A., I. Frommann, A. Koppara, S. Wolfsgruber, F. Jessen and M. Wagner, Face-Name Associative Recognition Deficits in Subjective Cognitive Decline and Mild Cognitive Impairment (3) 1185–1196
- Potkin, S.G., see Doran, E. (2) 459–470
- Potrony, M., see Tell-Marti, G. (3) 1065–1074
- Prasad, V., see Apostolova, I. (1) 197–204
- Prins, N.D., see Van Mierlo, L.D. (1) 249–259
- Puig, S., see Tell-Marti, G. (3) 1065–1074
- Puig-Butille, J.A., see Tell-Marti, G. (3) 1065–1074
- Putignano, D., see Gareri, P. (2) 557–565
- Putignano, S., see Gareri, P. (2) 557–565
- Qiu, W.Q., see Mohamed, L.A. (3) 1087–1099
- Qiu, W.Q., see Wang, E. (1) 47–61
- Querfurth, H.W., see Lee, H.-K. (3) 1015–1036
- Raffo, A., see Loewenstein, D.A. (3) 1119–1126
- Raghavendra, C.S., see Amen, D.G. (1) 261–273
- Raina, P., see Fenesi, B. (1) 297–303
- Rainero, I., see Ferrari, R. (4) 1271–1278
- Raji, C.A., see Amen, D.G. (1) 261–273
- Rao, E.R., see Liu, P. (2) 743–761
- Rasgon, N., see Sabbagh, M.N. (2) 441–446
- Rathore, N., see Haddick, P.C.G. (3) 1037–1054
- Rauchs, G., see Gaubert, M. (2) 717–731
- Raux, M., see Zerah, L. (1) 145–156
- Rea, R., see Carotenuto, A. (2) 805–815
- Reddy, P., see Shukla, V. (1) 335–349
- Reichl, J.H., see Liu, P. (2) 743–761
- Reijmer, Y.D., see Valenti, R. (4) 1223–1227
- Reinhardt, S., see Brandscheid, C. (2) 775–788
- Remes, A.M., see Suhonen, N.-M. (4) 1241–1251
- Reuter, M., see Kunz, L. (3) 1135–1144
- Riant, F., see Sellal, F. (1) 37–46
- Ricard-Blum, S., see Salza, R. (3) 991–1005
- Ricci, G., see Carotenuto, A. (2) 805–815
- Richards, D., see Sabbagh, M.N. (2) 441–446
- Ricordi, C., see Squitti, R. (3) 1055–1064
- Rietschel, M., see Khan, W. (3) 1159–1174
- Riley, G., see Valenti, R. (4) 1223–1227
- Rimondini, R., see Persson, T. (2) 601–617
- Riou, B., see Zerah, L. (1) 145–156
- Rissman, R.A., see Sokolow, S. (1) 229–237
- Roberts, A., see Apostolova, I. (1) 197–204
- Roffredo, L., see Monacelli, F. (2) 519–527
- Rognoni, T., see Matías-Guiu, J.A. (2) 733–742
- Romano, C., see Stoccoro, A. (4) 1451–1457
- Ronowska, A., see Zyśk, M. (3) 1145–1158
- Rosand, J., see Sellal, F. (1) 37–46
- Rosenberg, P.B., see Ismail, Z. (3) 929–938
- Rossi, G., see Ferrari, R. (4) 1271–1278
- Rotter, J.I., see Sokolow, S. (1) 229–237
- Rousseau, S., see Sellal, F. (1) 37–46
- Rovelet-Lecrux, A., see Sellal, F. (1) 37–46
- Rowe, C.C., see Sabbagh, M.N. (2) 441–446
- Rozemuller, A.J., see Louwersheimer, E. (1) 63–74
- Rubin, L.H., see Sundermann, E.E. (3) 947–957
- Rubino, E., see Ferrari, R. (4) 1271–1278
- Rubio-Rodrigo, M., see Persson, T. (2) 601–617
- Ruggiero, C., see Boccardi, V. (1) 239–248
- Sabbagh, M.N., B. Schäuble, K. Anand, D. Richards, S. Murayama, H. Akatsu, M. Takao, C.C. Rowe, C.L. Masters, H. Barthel, H.-J. Gertz, O. Peters, N. Rasgon, A. Jovalekic, O. Sabri, W.J. Schulz-Schaeffer and J. Seibyl, Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's Disease (2) 441–446
- Sabri, O., see Sabbagh, M.N. (2) 441–446
- Sager, M.A., see Law, L.L. (1) 351–359
- Saji, N., see Sugimoto, T. (2) 567–574
- Saka, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Sakowicz-Burkiewicz, M., see Zyśk, M. (3) 1145–1158

- Sakurai, T., see Kamikubo, Y. (2) 641–653
- Sakurai, T., see Sugimoto, T. (2) 567–574
- Salluzzo, M.G., see Stoccoro, A. (4) 1451–1457
- Salvadori, N., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Salza, R., C. Lethias and S. Ricard-Blum, The Multimerization State of the Amyloid- $\beta_{42}$  Peptide ( $A\beta_{42}$ ) Governs its Interaction Network with the Extracellular Matrix (3) 991–1005
- Sánchez-Muniz, F.J., see González-Muñoz, M.J. (3) 917–927
- Sanchez-Valle, R., see Tell-Martí, G. (3) 1065–1074
- Sanchez-Valle, R., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Sandebring-Matton, A., see Persson, T. (2) 601–617
- Santamaría, F., see Gareri, P. (2) 557–565
- Santana, I., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Scarpini, E., see Ferrari, R. (4) 1271–1278
- Scarpini, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Schäfer, K.-H., see Brandscheid, C. (2) 775–788
- Schäuble, B., see Sabbagh, M.N. (2) 441–446
- Schellenberg, G.D., see Haddick, P.C.G. (3) 1037–1054
- Scheltens, P., see Louwersheimer, E. (1) 63–74
- Scheltens, P., see Slot, R.E.R. (2) 687–697
- Scheltens, P., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Schneider, J., see Yarchoan, M. (2) 699–706
- Schneider, J.A., see Yu, L. (4) 1485–1493
- Schott, J.M., see Toombs, J. (3) 885–891
- Schreurs, B.G., see Brooks, S.W. (1) 185–196
- Schuck, F., see Brandscheid, C. (2) 775–788
- Schultz, S.A., see Law, L.L. (1) 351–359
- Schulz-Schaeffer, W.J., see Sabbagh, M.N. (2) 441–446
- Schumann, G., see Khan, W. (3) 1159–1174
- Schweizer, T.A., see Hird, M.A. (2) 447–452
- Schwartz, A., see Brandscheid, C. (2) 775–788
- Segkouli, S., see Zygouris, S. (2) 619–627
- Seibyl, J., see Sabbagh, M.N. (2) 441–446
- Seixas, A., see Agyemang, C. (1) 205–213
- Selfe, T.K., see Innes, K.E. (3) 899–916
- Sellal, F., D. Wallon, L. Martinez-Almoyna, C. Marelli, A. Dhar, H. Oesterlé, A. Rovelet-Lecrux, S. Rousseau, C.E. Kourkoulis, J. Rosand, Z.Y. DiPucchio, M. Frosch, C. Gombert, B. Audoin, M. Miné, F. Riant, T. Frebourg, D. Hannequin, D. Campion, S.M. Greenberg, E. Tournier-Lasserve and G. Nicolas, APP Mutations in Cerebral Amyloid Angiopathy with or without Cortical Calcifications: Report of Three Families and a Literature Review (1) 37–46
- Seo, J., see Shukla, V. (1) 335–349
- Seo, S.W., see Chang, K.J. (4) 1341–1348
- Serpente, M., see Ferrari, R. (4) 1271–1278
- Sha, L., see Wu, L. (3) 893–898
- Shah, R.C., see Yarchoan, M. (2) 699–706
- Shaw, L.M., see Timmers, M. (4) 1437–1449
- Shellington, E., see Heath, M. (1) 167–183
- Shen, L., L. Liao, C. Chen, Y. Guo, D. Song, Y. Wang, Y. Chen, K. Zhang, M. Ying, S. Li, Q. Liu and J. Ni, Proteomics Analysis of Blood Serums from Alzheimer's Disease Patients Using iTRAQ Labeling Technology (1) 361–378
- Shen, L., L. Liu and H.-F. Ji, Alzheimer's Disease Histological and Behavioral Manifestations in Transgenic Mice Correlate with Specific Gut Microbiome State (1) 385–390
- Shenhar-Tsarfaty, S., see Molad, J. (4) 1293–1299
- Shi, L., see Jia, J. (4) 1495–1504
- Shin, D.C., see Marmarelis, V.Z. (1) 89–105
- Shine, J.M., see McKinnon, A.C. (4) 1373–1384
- Shopin, L., see Molad, J. (4) 1293–1299
- Shu, H., see Su, F. (2) 491–507
- Shu, H., see Wang, Z. (1) 415–428
- Shua-Haim, J.R., see Boada, M. (1) 129–143
- Shukla, V., J. Seo, B.K. Binukumar, N.D. Amin, P. Reddy, P. Grant, S. Kuntz, S. Kesavapany, J. Steiner, S.K. Mishra, L.-H. Tsai and H.C. Pant, TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice (1) 335–349
- Siciliano, G., see Stoccoro, A. (4) 1451–1457
- Siegel, A.M., M.S. Barrett and M.T. Bhati, Deep Brain Stimulation for Alzheimer's Disease: Ethical Challenges for Clinical Research (2) 429–436
- Signori, A., see Monacelli, F. (2) 519–527
- Sikkens, S.A.M., see Van Mierlo, L.D. (1) 249–259
- Simmons, A., see Khan, W. (3) 1159–1174
- Simonelli, I., see Squitti, R. (3) 1055–1064
- Sims, R., see Morgan, A.R. (1) 25–36
- Singleton, A., see Ferrari, R. (4) 1271–1278
- Sistersmans, E.A., see Louwersheimer, E. (1) 63–74
- Slemmon, J., see Timmers, M. (4) 1437–1449
- Slot, R.E.R., A.C. Van Harten, M.I. Kester, W. Jongbloed, F.H. Bouwman, C.E. Teunissen, P. Scheltens, R. Veerhuis and W.M. van der Flier,

- Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly (2) 687–697
- Small, G.W., see Doran, E. (2) 459–470
- Smirne, N., see Boccardi, V. (1) 239–248
- Smith, E.E., see Ismail, Z. (3) 929–938
- Smith, G.S., see Ismail, Z. (3) 929–938
- Smits, M., see Meijboom, R. (2) 789–804
- Smolka, M.N., see Khan, W. (3) 1159–1174
- Soennessyn, H., see Bergland, A.K. (2) 575–584
- Soininen, H., see Imtiaz, B. (2) 453–458
- Soininen, H., see Khan, W. (3) 1159–1174
- Soininen, H., see Suhonen, N.-M. (4) 1241–1251
- Soininen, H., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Sokolow, S., X. Li, L. Chen, K.D. Taylor, J.I. Rotter, R.A. Rissman, P.S. Aisen and L.G. Apostolova, Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment (1) 229–237
- Solomon, A., see Imtiaz, B. (2) 453–458
- Solomon, J., see Gluzman, T. (1) 287–295
- Son, S.J., see Chang, K.J. (4) 1341–1348
- Song, D., see Shen, L. (1) 361–378
- Song, N., see Tan, L. (2) 629–640
- Song, Y.-Q., see Lin, T.-S. (3) 959–976
- Soriano, E., see Gomez-Ramos, A. (3) 977–990
- Spenger, C., see Khan, W. (3) 1159–1174
- Squitti, R., A.J. Mendez, I. Simonelli and C. Ricordi, Diabetes and Alzheimer's Disease: Can Elevated Free Copper Predict the Risk of the Disease? (3) 1055–1064
- Srinivasan, K., see Haddick, P.C.G. (3) 1037–1054
- Ståhlbom, A.K., see Li, X. (1) 327–334
- Stechl, E., see Apostolova, I. (1) 197–204
- Stein, J.H., see Law, L.L. (1) 351–359
- Steiner, J., see Shukla, V. (1) 335–349
- Steinhagen-Thiessen, E., see Apostolova, I. (1) 197–204
- Steketee, R.M.E., see Meijboom, R. (2) 789–804
- Stoccero, A., P. Tannorella, M.G. Salluzzo, R. Ferri, C. Romano, B. Naemias, G. Siciliano, L. Migliore and F. Coppedè, The Methylenetetrahydrofolate Reductase C677T Polymorphism and Risk for Late-Onset Alzheimer's disease: Further Evidence in an Italian Multicenter Study (4) 1451–1457
- Streffer, J.R., see Timmers, M. (4) 1437–1449
- Ströhle, A., see Khan, W. (3) 1159–1174
- Stronks, K., see Agyemang, C. (1) 205–213
- Su, F., H. Shu, Q. Ye, C. Xie, B. Yuan, Z. Zhang and F. Bai, Integration of Multilocus Genetic Risk into the Default Mode Network Longitudinal Trajectory during the Alzheimer's Disease Process (2) 491–507
- Sugimoto, H., see Kotani, R. (2) 529–542
- Sugimoto, T., M. Yoshida, R. Ono, S. Murata, N. Saji, S. Niida, K. Toba and T. Sakurai, Frontal Lobe Function Correlates with One-Year Incidence of Urinary Incontinence in Elderly with Alzheimer Disease (2) 567–574
- Suhonen, N.-M., I. Hallikainen, T. Hänninen, J. Jokelainen, J. Krüger, A. Hall, M. Pikkarainen, H. Soininen and A.M. Remes, The Modified Frontal Behavioral Inventory (FBI-mod) for Patients with Frontotemporal Lobar Degeneration, Alzheimer's Disease, and Mild Cognitive Impairment (4) 1241–1251
- Sultzner, D.L., see Ismail, Z. (3) 929–938
- Sun, N., see Chen, J. (2) 471–489
- Sun, S., see Tan, L. (2) 629–640
- Sun, X., see Loewenstein, D.A. (3) 1119–1126
- Sundermann, E.E., A. Biegton, L.H. Rubin, R.B. Lipton, S. Landau and P.M. Maki for the Alzheimer's Disease Neuroimaging Initiative, Does the Female Advantage in Verbal Memory Contribute to Underestimating Alzheimer's Disease Pathology in Women versus Men? (3) 947–957
- Sundström, E., see Persson, T. (2) 601–617
- Szűcs, A., see Horváth, A. (3) 1175–1183
- Szutowicz, A., see Zyśk, M. (3) 1145–1158
- Taddei, K., see Peters, K.E. (3) 1127–1133
- Tagliavini, F., see Ferrari, R. (4) 1271–1278
- Tai pale, H., see Koponen, M. (1) 107–118
- Tai pale, H., see Lampela, P. (1) 119–128
- Takada, A., see Kuriyama, N. (4) 1253–1262
- Takao, M., see Sabbagh, M.N. (2) 441–446
- Takasugi, N., see Kamikubo, Y. (2) 641–653
- Takeda, K., see Kuriyama, N. (4) 1253–1262
- Tamura, A., see Kuriyama, N. (4) 1253–1262
- Tan, L., H. Yang, W. Pang, H. Li, W. Liu, S. Sun, N. Song, W. Zhang and Y. Jiang, Investigation on the Role of BDNF in the Benefits of Blueberry Extracts for the Improvement of Learning and Memory in Alzheimer's Disease Mouse Model (2) 629–640
- Tang, Y., see Jia, J. (4) 1495–1504
- Tannorella, P., see Stoccero, A. (4) 1451–1457

- Tanskanen, A., see Koponen, M. (1) 107–118
- Tanskanen, A., see Lampela, P. (1) 119–128
- Tapias, V., see Fitz, N.F. (3) 1075–1085
- Tarducci, R., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Tárraga, L., see Boada, M. (1) 129–143
- Tarumi, T., see Marmarelis, V.Z. (1) 89–105
- Taylor, K.D., see Sokolow, S. (1) 229–237
- Tell-Martí, G., J.A. Puig-Butille, M. Potrony, E. Plana, C. Badenas, A. Antonell, R. Sanchez-Valle, J.L. Molinuevo, A. Lleó, D. Alcolea, J. Fortea, R. Fernández-Santiago, J. Clarimón, A. Lladó and S. Puig, A Common Variant in the *MCIR* Gene (p.V92M) is associated with Alzheimer's Disease Risk (3) 1065–1074
- Terpening, Z., see McKinnon, A.C. (4) 1373–1384
- Tesseur, I., see Timmers, M. (4) 1437–1449
- Teunissen, C., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Teunissen, C.E., see Slot, R.E.R. (2) 687–697
- Theunis, C., O. Adolfsson, N. Crespo-Biel, K. Piorkowska, M. Pihlgren, D.T. Hickman, V. Gafner, P. Borghgraef, H. Devijver, A. Pfeifer, F. Van Leuven and A. Muhs, Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope (2) 585–599
- Thevarkunnel, S., see Borghys, H. (2) 763–774
- Thordardottir, S., see Li, X. (1) 327–334
- Thygesen, L.C., L.N. Gimsing, A. Bautz, N.C. Hvidt and C. Johansen, Chronic Neurodegenerative Illnesses and Epilepsy in Danish Adventists and Baptists: A Nationwide Cohort Study (4) 1429–1435
- Tiihonen, J., see Koponen, M. (1) 107–118
- Tiihonen, J., see Lampela, P. (1) 119–128
- Timmers, M., S. Barão, B. Van Broeck, I. Tesseur, J. Slemmon, K. De Waepenaert, J. Bogert, L.M. Shaw, S. Engelborghs, D. Moechars, M. Mercken, L. Van Nueten, L. Tritsmans, B. de Strooper and J.R. Streffler BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants (4) 1437–1449
- Titheridge, S., see Heath, M. (1) 167–183
- Toba, K., see Sugimoto, T. (2) 567–574
- Tokuda, T., see Kuriyama, N. (4) 1253–1262
- Tolppanen, A.M., see Imtiaz, B. (2) 453–458
- Tolppanen, A.-M., see Koponen, M. (1) 107–118
- Tolppanen, A.-M., see Lampela, P. (1) 119–128
- Toombs, J., M.S. Foiani, R.W. Paterson, A. Heslegrave, S. Wray, J.M. Schott, N.C. Fox, M.P. Lunn, K. Blennow and H. Zetterberg, Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- $\beta$  Concentration (3) 885–891
- Torkildsen, C.G., see Ebel, D.L. (3) 1197–1211
- Torres, M., see Boada, M. (1) 129–143
- Totoiu, M., see Doran, E. (2) 459–470
- Touchard, S., see Morgan, A.R. (1) 25–36
- Tourette, C., see Zerah, L. (1) 145–156
- Tournier-Lasserre, E., see Sellal, F. (1) 37–46
- Traini, E., see Carotenuto, A. (2) 805–815
- Tremblay, S., see Castellano, C.-A. (4) 1459–1468
- Tritsmans, L., see Timmers, M. (4) 1437–1449
- Tsai, H.-J., see Lin, T.-S. (3) 959–976
- Tsai, L.-H., see Shukla, V. (1) 335–349
- Tsolaki, M., see Khan, W. (3) 1159–1174
- Tsolaki, M., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Tsolaki, M., see Zygouris, S. (2) 619–627
- Tucker, D., see Lu, Y. (4) 1469–1484
- Tufts, E., see Last, N. (1) 275–286
- Tzovaras, D., see Zygouris, S. (2) 619–627
- Urano, Y., see Kotani, R. (2) 529–542
- Urbani, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Vaartjes, I., see Agyemang, C. (1) 205–213
- Valcarcel, B., see Ho, L. (1) 305–315
- Valenti, R., A. Charidimou, L. Xiong, G. Boulouis, P. Fotiadis, A. Ayres, G. Riley, H.J. Kuijf, Y.D. Reijmer, L. Pantoni, M.E. Gurol, S. Davidsdottir, S.M. Greenberg and A. Viswanathan, Visuospatial Functioning in Cerebral Amyloid Angiopathy: A Pilot Study (4) 1223–1227
- Valles-Salgado, M., see Matías-Guiu, J.A. (2) 733–742
- Van Broeck, B., see Borghys, H. (2) 763–774
- Van Broeck, B., see Timmers, M. (4) 1437–1449
- van de Vorst, I.E., see Agyemang, C. (1) 205–213
- van der Brug, M., see Haddick, P.C.G. (3) 1037–1054
- Van der Flier, W.M., see Louwersheimer, E. (1) 63–74
- van der Flier, W.M., see Slot, R.E.R. (2) 687–697
- Van der Flier, W.M., see Van Mierlo, L.D. (1) 249–259
- van der Lugt, A., see Meijboom, R. (2) 789–804
- van Duijn, C.M., see Louwersheimer, E. (1) 63–74
- Van Harten, A.C., see Slot, R.E.R. (2) 687–697

- Van Hout, H.P.J., see Van Mierlo, L.D. (1) 249–259  
 Van Leuven, F., see Theunis, C. (2) 585–599  
 Van Mierlo, L.D., H. Wouters, S.A.M. Sikkes, W.M.  
     Van der Flier, N.D. Prins, J.A.E. Bremer, T.  
     Koene and H.P.J. Van Hout, Screening for  
     Mild Cognitive Impairment and Dementia with  
     Automated, Anonymous Online and Telephone  
     Cognitive Self-Tests (1) 249–259  
 Van Nueten, L., see Timmers, M. (4) 1437–1449  
 van Swieten, J.C., see Louwersheimer, E. (1) 63–74  
 van Swieten, J.C., see Meijboom, R. (2) 789–804  
 van Waalwijk van Doorn, L.J.C., J.D. Gispert,  
     H.B. Kuiperij, J.A.H.R. Claassen, A. Arighi,  
     I. Baldeiras, K. Blennow, M. Bozzali, M.  
     Castelo-Branco, E. Cavedo, D.D. Emek-Savaş,  
     E. Eren, P. Eusebi, L. Farotti, C. Fenoglio, J.F.  
     Ormaechea, Y. Freund-Levi, G.B. Frisoni, D.  
     Galimberti, S. Genc, V. Greco, H. Hampel, S.-  
     K. Herukka, Y. Liu, A. Lladó, A. Lleó, F.M.  
     Nobili, K.K. Oguz, L. Parnetti, J. Pereira,  
     A. Picco, M. Pikkarainen, C.R. de Oliveira,  
     E. Saka, N. Salvadori, R. Sanchez-Valle, I.  
     Santana, E. Scarpini, P. Scheltens, H. Soininen,  
     R. Tarducci, C. Teunissen, M. Tsolaki, A.  
     Urbani, E. Vilaplana, P.J. Visser, A.K. Wallin,  
     G. Yener, J.L. Molinuevo, O. Meulenbroek and  
     M.M. Verbeek, Improved Cerebrospinal Fluid-  
     Based Discrimination between Alzheimer's  
     Disease Patients and Controls after Correction  
     for Ventricular Volumes (2) 543–555  
 Vasiliev, A.V., see Dashinimaev, E.B. (2) 835–847  
 Vassar, R., see Liu, P. (2) 743–761  
 Veerhuis, R., see Slot, R.E.R. (2) 687–697  
 Vellas, B., see Khan, W. (3) 1159–1174  
 Verbeek, M.M., see van Waalwijk van Doorn, L.J.C.  
     (2) 543–555  
 Verny, M., see Zerah, L. (1) 145–156  
 Vesely, K.A., see Hird, M.A. (2) 447–452  
 Vilaplana, E., see van Waalwijk van Doorn, L.J.C.  
     (2) 543–555  
 Villain, N., see Gaubert, M. (2) 717–731  
 Villemagne, V.L., see Khan, W. (3) 1159–1174  
 Visser, P.J., see van Waalwijk van Doorn, L.J.C. (2)  
     543–555  
 Viswanathan, A., see Valenti, R. (4) 1223–1227  
 Vorotelyak, E.A., see Dashinimaev, E.B. (2) 835–847  
 Votis, K., see Zygouris, S. (2) 619–627  
 Wagner, M., see Polcher, A. (3) 1185–1196  
 Wahlund, L.-O., see Khan, W. (3) 1159–1174  
 Wahlund, L.-O., see Li, X. (1) 327–334  
 Waldemar, G., see Nørgaard, A. (2) 707–716  
 Wallack, M., see Wang, E. (1) 47–61  
 Wallin, A.K., see van Waalwijk van Doorn, L.J.C. (2)  
     543–555  
 Wallon, D., see Sellal, F. (1) 37–46  
 Wang, E., H. Zhu, X. Wang, A.C. Gower, M. Wallack,  
     J.K. Blusztajn, N. Kowall and W.Q. Qiu,  
     Amylin Treatment Reduces Neuroinflammation  
     and Ameliorates Abnormal Patterns of Gene  
     Expression in the Cerebral Cortex of an  
     Alzheimer's Disease Mouse Model (1) 47–61  
 Wang, E., see Mohamed, L.A. (3) 1087–1099  
 Wang, H., X. Hong and Y. Wang, Mitochondrial  
     Repair Effects of Oxygen Treatment on  
     Alzheimer's Disease Model Mice Revealed by  
     Quantitative Proteomics (3) 875–883  
 Wang, L., see Li, L. (4) 1403–1417  
 Wang, Q., W.-X. Li, S.-X. Dai, Y.-C. Guo, F.-F.  
     Han, J.-J. Zheng, G.-H. Li and J.-F. Huang,  
     Meta-Analysis of Parkinson's Disease and  
     Alzheimer's Disease Revealed Commonly  
     Impaired Pathways and Dysregulation of  
     NRF2-Dependent Genes (4) 1525–1539  
 Wang, R., see Lu, Y. (4) 1469–1484  
 Wang, X., see Li, L. (4) 1403–1417  
 Wang, X., see N'Songo, A. (4) 1215–1222  
 Wang, X., see Wang, E. (1) 47–61  
 Wang, X., see Wu, L. (3) 893–898  
 Wang, Y., see Shen, L. (1) 361–378  
 Wang, Y., see Wang, H. (3) 875–883  
 Wang, Z., Z. Dai, H. Shu, D. Liu, Q. Guo, Y. He and Z.  
     Zhang, Cortical Thickness and Microstructural  
     White Matter Changes Detect Amnestic Mild  
     Cognitive Impairment (1) 415–428  
 Wangmo, T., see Ienca, M. (4) 1301–1340  
 Watanabe, I., see Kuriyama, N. (4) 1253–1262  
 Watanabe, Y., see Kuriyama, N. (4) 1253–1262  
 Watts, R.J., see Haddick, P.C.G. (3) 1037–1054  
 Wei, C., see Jia, J. (4) 1495–1504  
 Weiss, M.M., see Louwersheimer, E. (1) 63–74  
 Westman, E., see Khan, W. (3) 1159–1174  
 Westman, E., see Li, X. (1) 327–334  
 Willette, A.A., see McLimans, K.E. (1) 403–413  
 Williams, J., see Morgan, A.R. (1) 25–36  
 Williams, S.C.R., see Khan, W. (3) 1159–1174  
 Wilson, R.S., see Yarchaoan, M. (2) 699–706  
 Wilson, R.S., see Yu, L. (4) 1485–1493  
 Wittwer, J., see Pimouguet, C. (2) 509–517  
 Wolfsgruber, S., see Polcher, A. (3) 1185–1196  
 Wood, J.P.M., see Chidlow, G. (2) 655–675  
 Wouters, H., see Van Mierlo, L.D. (1) 249–259

- Wray, S., see Toombs, J. (3) 885–891
- Wright, C., see Loewenstein, D.A. (3) 1119–1126
- Wright, C.E., see Betrie, A.H. (2) 849–860
- Wu, L., J. Liu, L. Sha, X. Wang, J. Li, J. Dong and J. Jia, Sporadic Cases with Novel Mutations and Pedigree in Hereditary Leukoencephalopathy with Axonal Spheroids (3) 893–898
- Xiao, C., see Chen, J. (2) 471–489
- Xie, B., Y. Xu, Z. Liu, W. Liu, L. Jiang, R. Zhang, D. Cui, Q. Zhang and S. Xu, Elevation of Peripheral BDNF Promoter Methylation Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer's Disease: A 5-Year Longitudinal Study (1) 391–401
- Xie, C., see Su, F. (2) 491–507
- Xiong, L., see Valenti, R. (4) 1223–1227
- Xu, J., see Hu, C. (4) 1263–1269
- Xu, S., see Li, L. (4) 1403–1417
- Xu, S., see Xie, B. (1) 391–401
- Xu, X., see Hu, C. (4) 1263–1269
- Xu, Y., see Xie, B. (1) 391–401
- Yamada, K., see Kuriyama, N. (4) 1253–1262
- Yamasaki, S., see Nakanishi, M. (2) 817–824
- Yang, H., see Tan, L. (2) 629–640
- Yarchoan, M., B.D. James, R.C. Shah, Z. Arvanitakis, R.S. Wilson, J. Schneider, D.A. Bennett and S.E. Arnold, Association of Cancer History with Alzheimer's Disease Dementia and Neuropathology (2) 699–706
- Ye, Q., see Su, F. (2) 491–507
- Yener, G., see van Waalwijk van Doorn, L.J.C. (2) 543–555
- Ying, M., see Shen, L. (1) 361–378
- Yoshida, M., see Sugimoto, T. (2) 567–574
- Younesi, E., see Emon, M.A.E.K. (2) 677–686
- Younkin, S.G., see N'Songo, A. (4) 1215–1222
- Yu, L., R.S. Wilson, J.A. Schneider, D.A. Bennett and P.A. Boyle, Financial and Health Literacy Predict Incident Alzheimer's Disease Dementia and Pathology (4) 1485–1493
- Yuan, B., see Su, F. (2) 491–507
- Zahs, K.R., see Liu, P. (2) 743–761
- Zeng, L., see Hu, C. (4) 1263–1269
- Zerah, L., J. Cohen-Bittan, M. Raux, A. Meziere, C. Tourette, C. Neri, M. Verny, B. Riou, F. Khiami and J. Boddaert, Association between Cognitive Status before Surgery and Outcomes in Elderly Patients with Hip Fracture in a Dedicated Orthogeriatric Care Pathway (1) 145–156
- Zetterberg, H., see Toombs, J. (3) 885–891
- Zhan, L., see Chen, J. (2) 471–489
- Zhang, K., see Shen, L. (1) 361–378
- Zhang, Q., see Lu, Y. (4) 1469–1484
- Zhang, Q., see Xie, B. (1) 391–401
- Zhang, R., see Marmarelis, V.Z. (1) 89–105
- Zhang, R., see Xie, B. (1) 391–401
- Zhang, W., see Tan, L. (2) 629–640
- Zhang, Z., see Su, F. (2) 491–507
- Zhang, Z., see Wang, Z. (1) 415–428
- Zhao, X., see Li, L. (4) 1403–1417
- Zheng, J.-J., see Wang, Q. (4) 1525–1539
- Zhou, A., see Jia, J. (4) 1495–1504
- Zhu, H., see Mohamed, L.A. (3) 1087–1099
- Zhu, H., see Wang, E. (1) 47–61
- Zygouris, S., K. Ntovas, D. Giakoumis, K. Votis, S. Doumpoulakis, S. Segkouli, C. Karagiannidis, D. Tzovaras and M. Tsolaki, A Preliminary Study on the Feasibility of Using a Virtual Reality Cognitive Training Application for Remote Detection of Mild Cognitive Impairment (2) 619–627
- Zyśk, M., H. Bielarczyk, S. Gul-Hinc, A. Dyś, B. Gapys, A. Ronowska, M. Sakowicz-Burkiewicz and A. Szutowicz, Phenotype-Dependent Interactions between N-acetyl-L-Aspartate and Acetyl-CoA in Septal SN56 Cholinergic Cells Exposed to an Excess of Zinc (3) 1145–1158